
zzso zzso a selective zzso zzso zzso inhibitor of zzso and zzso is currently licensed for the treatment of zzso or zzso gastrointestinal zzso zzso zzso which are zzso zzso zzso response rates in zzso of patients and stable disease in zzso of patients are typically zzso The aim of this study was to assess the effectiveness and toxicity of an zzso cohort of patients treated with zzso zzso and to compare these results with published zzso 

A retrospective audit of the use of zzso zzso in zzso within the zzso Cancer Network was carried zzso In total, 39 patients were identified, the first commenced zzso zzso in September zzso 

The most common primary zzso sites were small zzso (19 zzso and stomach (12 zzso zzso zzso zzso was carried out in 21 zzso zzso zzso in three zzso and 15 zzso were zzso Of those who had zzso zzso the median time to recurrence was 13 months zzso zzso Common sites of zzso were liver (19 zzso and zzso (12 zzso At 24 months zzso remained on zzso A partial response was reported in 23 zzso stable disease in seven zzso and disease progression in four zzso Five patients zzso have yet to be zzso at 3 zzso zzso was well tolerated with minor zzso zzso zzso zzso zzso skin rash (four zzso minor gastrointestinal bleed (one zzso No significant toxicity was documented in 18 zzso 

The response rates achieved in this zzso cohort of patients are consistent with published zzso The duration of zzso control is good, with most patients responding to zzso zzso for more than 2 zzso zzso are mild and zzso 

